Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
- Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
- Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 60
- Registration Number
- NCT00796679
- Locations
- 🇭🇰
University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
Vitamin D and Coronary Calcification Study
- Conditions
- Interventions
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Joslin Diabetes Center
- Target Recruit Count
- 44
- Registration Number
- NCT00752102
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Abbott
- Target Recruit Count
- 107
- Registration Number
- NCT00701805
Immune Effects of Vitamin D in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2009-05-13
- Lead Sponsor
- Renal Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00686751
- Locations
- 🇺🇸
Upper Manhattan Dialysis Center, New York, New York, United States
🇺🇸Yorkville Dialysis Center, New York, New York, United States
🇺🇸Irving Place Dialysis Center, New York, New York, United States
Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 153
- Registration Number
- NCT00667576
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 13
- Registration Number
- NCT00664430
- Locations
- 🇧🇷
Site Reference ID/Investigator# 7118, Sao Paulo, Brazil
🇧🇷Site Reference ID/Investigator# 7114, Sao Paulo, Brazil
Paricalcitol Injection Phase II Trial
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 25
- Registration Number
- NCT00646932
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT00637897
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
- Conditions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 2
- Registration Number
- NCT00634582
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Chinese University of Hong Kong
- Registration Number
- NCT00599963
- Locations
- 🇭🇰
Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.